Shomron Ben-Horin

Shomron Ben-Horin (; born 1968, Tel Aviv) is an Israeli physician, a co-founder & Chief Medical Officer of Evinature, and professor of medicine at the Tel-Aviv University.

He received his MD from the Hadassah School of Medicine of the Hebrew University of Jerusalem before completing his gastroenterology training at Sheba Medical Center in Tel Aviv.

Medical career

Ben-Horin is the chief of the Gastroenterology Department at Sheba Medical Center, Israel. He was previously Director of the inflammatory bowel disease service at the Sheba Gastroenterology Department.

He was a postdoctoral scientist in the laboratory of human immunology at NewYork-Presbyterian Hospital, and in 2015, was an adjunct professor of medicine at the 1st Affiliated Hospital of Sun Yat-sen University, Guangzhou, China.

After his successful trial on CurQD for patients with ulcerative colitis, Ben-Horin founded Evinature with his research partner, Nir Salomon in 2020.

Professional organizations

Ben-Horin is the president of the Israel IBD Society. He has served as associate editor of the Journal of Crohn's & Colitis (JCC) and is currently a member of the editorial board of Gut (journal) and the Scientific Committee of the European Crohn's & Colitis Organization (ECCO).

He has also served as a member of the steering committee of the Israeli Gastro Association and is the director of IBD Passport, a web-based global support program for traveling IBD patients.

Clinical and scientific fields of interest

Ben-Horin's main research focus is drug mechanisms, therapeutic drug monitoring and immunogenicity of biologics, response to biologic antibody drugs in IBD, and opportunistic infections in IBD. He has authored several hundred peer-reviewed articles, cited over 21,000 times, and served as the principal investigator and sub-investigator in over 20 clinical trials, notably two multi-center prospective randomized controlled trials: Comparison of steroids+5ASA versus steroids alone in acute severe UC (7 sites in Israel, Europe, China and Korea) and one placebo-controlled RCT of Curcumin as add-on therapy for mild-moderate active UC (Israel, Cyprus and Hong-Kong).

Selected publications